"As a hematologist/oncologist specializing in lymphoma, I know that it’s possible to obtain genetic and molecular details on each patient’s cancer, and that this information can offer potentially lifesaving clues. But we don’t always know which molecular diagnostic test is appropriate for each patient.
When we do obtain genetic sequence data, it’s often unclear what it means for a patient’s prognosis. It’s hard to select the most promising medicine when different studies point to different applications. For example, several inhibitors of the enzyme anaplastic lymphoma kinase (ALK) have proven effective in treating lymphoma, non-small cell lung cancer, and neuroblastoma, while other findings suggest one of the inhibitors can treat pediatric oncology patients.
In theory, these findings should empower oncologists to find treatments that precisely fit each cancer and achieve better outcomes for patients. But in practice, oncologists are now confronted with a firehose of information that is too much to fully take in. As a result, cancer care is often not as personalized as it could be."
In Oncode, we are hematologists and oncologists best partner in precision medicine. From guiding clinicians to select the most appropriate molecular diagnostic test(s), to providing the most concise report suggesting treatment options and next steps, to technical consultation by our professional team, we support clinicians in all way possible to achieve better outcomes for patients. We know how difficult it is to apply precision medicine in actual clinical practice, and our job is to make it easier and applicable so that precision medicine can be easily accessible to all. ... See more
